Metoject (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folate into its active form. This interruption reduces the synthesis of DNA, RNA and proteins, especially in rapidly dividing cells such as immune‑active lymphocytes and cancer cells, thereby providing immunosuppressive and antineoplastic effects.

The dose of Metoject is individualized by the prescribing clinician based on the specific indication, disease severity, patient weight, renal and hepatic function, and response to therapy. No fixed dosing schedule is provided here; the prescriber sets the appropriate regimen.

Methotrexate is generally contraindicated in pregnancy because it can cause fetal malformations and miscarriage. Women of child‑bearing potential should use effective contraception while on therapy. Breastfeeding is also discouraged, as the drug can be excreted in milk. Consultation with a healthcare professional is essential.

To request Metoject, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Metoject (methotrexate) is a folate antagonist, differing from biologic agents that target specific cytokines. It is often less expensive and can be used as a first‑line disease‑modifying drug, but it requires regular laboratory monitoring for toxicity. Biologics may have a more targeted safety profile but are typically higher‑cost options.

Metoject should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not freeze the product. Follow standard aseptic techniques when preparing the subcutaneous injection to maintain sterility.

Metoject is given by subcutaneous injection, usually into the abdomen or thigh. The injection site should be rotated to reduce local irritation. Administration is performed by a qualified healthcare professional or a trained patient following proper aseptic technique and dosage instructions from the prescriber.

Serious adverse events include severe liver toxicity, pulmonary fibrosis, profound bone‑marrow suppression leading to pancytopenia, and opportunistic infections due to immunosuppression. Patients should report symptoms such as persistent jaundice, shortness of breath, unusual bruising or infections promptly to their clinician.

Metoject should be avoided in individuals with known severe hepatic disease, significant renal impairment, active infections, or hypersensitivity to methotrexate. It is also contraindicated in pregnant women and those planning conception without appropriate contraception. Clinicians must assess each patient’s medical history before initiating therapy.